Related Experiment Video
Updated: Jan 7, 2026
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
Genetic insights and diagnostic challenges in inherited bone marrow failure syndromes: a comprehensive study from a
Syed Ibrahim Bukhari1, Fizza Akbar2, Salman Kirmani2
1Department of Oncology, Aga Khan University, Karachi, Pakistan.
Insights
Genetic testing accurately diagnosed inherited bone marrow failure syndromes (IBMFS) in 34% of pediatric patients, improving management and family counseling. This highlights the importance of genetic evaluation for bone marrow failure, especially in consanguineous populations.
Area of Science:
- Hematology
- Genetics
- Pediatric Medicine
Background:
- Inherited bone marrow failure syndromes (IBMFS) often present with overlapping symptoms, leading to misdiagnosis as idiopathic aplastic anemia (iAA).
- Accurate diagnosis is crucial, particularly in populations with high rates of consanguinity.
- Genetic testing plays a pivotal role in differentiating IBMFS from iAA and other conditions.
Purpose of the Study:
- To evaluate the diagnostic yield and clinical impact of genetic testing in pediatric patients with suspected bone marrow failure.
- To assess the utility of genetic testing in a consanguineous population.
- To identify common genetic variants associated with IBMFS in the studied cohort.
Main Methods:
- Retrospective analysis of 41 pediatric patients undergoing genetic evaluation for bone marrow failure.
- Review of clinical features, initial diagnoses, and genetic testing results.
- Assessment of diagnostic revisions and impact on patient management and family counseling.
Main Results:
- Genetic testing identified pathogenic/likely pathogenic variants in 34% of patients, establishing a molecular diagnosis for IBMFS.
- An additional 32% had variants of uncertain significance, with one later reclassified, confirming Noonan syndrome.
- Initial diagnoses were revised to conditions such as Fanconi anemia, Congenital Amegakaryocytic Thrombocytopenia, Shwachman-Diamond syndrome, and Diamond-Blackfan anemia.
- Commonly implicated genes included *MPL*, *FANCA*, and *DANJC21*.
Conclusions:
- Genetic testing achieved a 34% diagnostic yield for IBMFS in this Pakistani cohort, consistent with global findings.
- Molecular diagnosis enhanced precision, guided treatment, and facilitated family counseling.
- High rates of variants of uncertain significance necessitate ongoing reclassification and multidisciplinary care approaches.
Background:
Inherited bone marrow failure syndromes (IBMFS) often present with overlapping features and may be misdiagnosed as idiopathic aplastic anemia (iAA). Genetic testing is critical for accurate diagnosis, especially in consanguineous populations.
Research Design And Methods:
We retrospectively analyzed 41 pediatric patients who underwent genetic evaluation for suspected bone marrow failure. Clinical features, diagnostic classifications, and genetic findings were reviewed to assess diagnostic yield and impact.
Results:
The cohort included 21 males and 20 females (median age: 8 years). Pancytopenia was the most common presentation (27/41; 65%), half (20/41; 49%) were products of consanguineous marriage. iAA was the initial diagnosis in 56% (23/41). Genetic testing identified pathogenic/likely pathogenic (P/LP) variants in 14 patients (34%), enabling a molecular diagnosis. An additional 13 patients (32%) had variants of uncertain significance, one of which was later reclassified as LP, confirming Noonan syndrome. Genetic findings prompted diagnostic revisions, including Fanconi anemia, Congenital Amegakaryocytic Thrombocytopenia, Shwachman-Diamond syndrome, and Diamond-Blackfan anemia. Commonly affected genes included MPL, FANCA, followed by DANJC21.
Conclusions:
In this Pakistani cohort, genetic testing clarified IBMFS diagnoses in 34% of cases, matching global yields. It enhanced diagnostic precision, informed management, and supported family counseling, though high VUS rates underscore the need for ongoing reclassification and multidisciplinary care.
